Method to Use Therapeutic Microencapsulation of Embedding Parathyroid Live Cells with Theracyte

• US 20080260792A1
• Filed: 06/02/2008
• Published: 10/23/2008
• Est. Priority Date: 03/02/2006
• Status: Abandoned Application

• Current Assignee: Non-Profit Organization Chang Gung Memorial Hospital
• Original Assignee: Non-Profit Organization Chang Gung Memorial Hospital
• Inventors: Chou, Fong-Fu
• Application Number:
  US12/131,463
• Publication Number:
  US 20080260792A1
• Time in Patent Office: Days
• US Class Current: 424/422
• CPC Class Codes: A61K 35/55 Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders

Abstract

A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in −179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×10⁵ parathyroid live cells in the TheraCyte to manufacture the therapeutic microencapsulation; (3) implanting the therapeutic microencapsulation into a mammal object inside hypoderm, wherein the parathyroid live cells are not rejected and can last alive for four months; and (4) the therapeutic microencapsulation continues to generate parathyroid hormone to increase bone mineral density so as to avoid side effects, such as raising the level of calcium or lowering the level of phosphorus in blood.

Claims

1. A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte®

, comprising the steps of;

(1) containing the parathyroid live cells in −

179°

C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation;

(2) embedding at least 4×

10⁵ parathyroid live cells in the TheraCyte®

to manufacture the therapeutic microencapsulation;

(3) implanting the therapeutic microencapsulation into a mammal object inside hypoderm, wherein the parathyroid live cells are not rejected and can last alive for four months; and

(4) the therapeutic microencapsulation continues to generate parathyroid hormone to increase bone mineral density so as to avoid side effects, such as raising the level of calcium or lowering the level of phosphorus in blood.

2. The method as claimed in claim 1, wherein the therapeutic microencapsulation containing 4×

10⁶ parathyroid live cells in the TheraCyte®

is implanted into the hypoderm.

3. The method as claimed in claim 1, wherein the therapeutic microencapsulation containing 4×

10⁷ parathyroid live cells in the TheraCyte®

is implanted into the hypoderm.

4. The method as claimed in claim 1, wherein the therapeutic microencapsulation containing at least 200×

4×

10⁵ parathyroid live cells in the TheraCyte®

is implanted into the hypoderm for treating humans.

5. The method as claimed in claim 1, wherein the therapeutic microencapsulation containing 200×

4×

10⁶ parathyroid live cells in the TheraCyte®

is implanted into the hypoderm for treating humans.